Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma

PHASE3UnknownINTERVENTIONAL
Timeline

Start Date

March 31, 2000

Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
DRUG

Wobe-Mugos E

DRUG

melphalan

DRUG

prednisone

PROCEDURE

quality-of-life assessment

Trial Locations (19)

11235

HemOnCare, P.C., Brooklyn

20735

Oncology-Hematology Associates, P.A., Clinton

33133

Oncology Radiation Associates, Miami

33901

Florida Cancer Specialists, Fort Myers

38117

West Clinic, P.C., Memphis

46202

Indiana Community Cancer Care, Inc., Indianapolis

58501

Medcenter One Health System, Bismarck

Mid Dakota Clinic, P.C., Bismarck

62526

Cancer Care Specialists of Central Illinois, S.C., Decatur

64131

Oncology Hematology Associates of Kansas City, Kansas City

85032

Southwest Clinical Research, Incorporated, Phoenix

85712

Arizona Clinical Research Center, Tucson

91505

Providence Saint Joseph Medical Center - Burbank, Burbank

92064

Southwest Cancer Care, Poway

92262

Comprehensive Cancer Centers of the Desert, Palm Springs

93309

Comprehensive Blood and Cancer Center, Bakersfield

94704

Alta Bates Comprehensive Cancer Center, Berkeley

98405

Hematology Oncology Northwest, P.C., Tacoma

04074

Maine Center for Cancer Medicine and Blood Disorders, Scarborough

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Medsearch

INDUSTRY

NCT00014339 - Chemotherapy With or Without Wobe-Mugos E in Treating Patients With Stage II or Stage III Multiple Myeloma | Biotech Hunter | Biotech Hunter